Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

QIAGEN launches QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus in Europe following CE marking
QIAGEN launches QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus in Europe following CE marking


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has obtained CE marking for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro

Agilent Technologies Announces Cash Dividend of 18 Cents Per Share
Agilent Technologies Announces Cash Dividend of 18 Cents Per Share


Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on April 22, 2020, to all shareholders of record as of the close of

Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns
Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns


Pfizer Inc. (NYSE: PFE) announced today that given the unique circumstances of the COVID-19 pandemic and Pfizer’s responsibility to prioritize the health and safety of colleagues and invited

 Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch
 Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch


Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational

Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older
Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older


Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine

Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team
Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team


Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that

IMV Inc. Establishes At-the-Market Facility
IMV Inc. Establishes At-the-Market Facility


IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated March 18

IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19
IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19


IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based vaccine candidate

Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings
Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today

Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay
Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

QIAGEN Dramatically Ramping Up Global Production Capacity for RNA Extraction Kits for Use in Detection of SARS-CoV-2 Coronavirus
QIAGEN Dramatically Ramping Up Global Production Capacity for RNA Extraction Kits for Use in Detection of SARS-CoV-2 Coronavirus


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the

Agilent Technologies to Adjourn Annual Meeting Until April 17, 2020
Agilent Technologies to Adjourn Annual Meeting Until April 17, 2020


Agilent Technologies, Inc. (NYSE: A) today announced plans to adjourn its annual meeting of stockholders, originally scheduled to be held March 18, 2020, due to public health considerations

NANOBIOTIX 2019 Annual Results
NANOBIOTIX 2019 Annual Results


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005789/en/



Pipeline (Graphic: NANOBIOTIX)




NANOBIOTIX

Humana Foundation Donates $500,000 in Support of Coronavirus Pandemic Relief and Recovery Efforts
Humana Foundation Donates $500,000 in Support of Coronavirus Pandemic Relief and Recovery Efforts


The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), announced today it will provide $500,000 in support of coronavirus (COVID-19) relief and recovery efforts, partnering with three

Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts
Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts


Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 28, 2020. The purpose

Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results
Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial

Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland
Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine
Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine


Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution

American Renal Associates Holdings, Inc. Announces Fourth Quarter 2019 Results
American Renal Associates Holdings, Inc. Announces Fourth Quarter 2019 Results


American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and

Drägerwerk: Die Bundesregierung redet ein großes Wörtchen mit!
Drägerwerk: Die Bundesregierung redet ein großes Wörtchen mit!

Es war der nächste schwarze Montag an den Börsen – eine der ganz wenigen Ausnahmeerscheinungen ist die Aktie von Drägerwerk (WKN: 555060). Der unscheinbare Titel aus dem SDAX ging heute mit einem

Geratherm: Explosion nach Corona-News!
Geratherm: Explosion nach Corona-News!

Die explosivsten Wertsteigerungen verzeichnen in Corona-Zeiten Aktien von Unternehmen, deren Präparate oder Produkte zur Eindämmung oder Bekämpfung des COVID-19-Virus dienen. Die heutige News von Ge

Premier Inc. Survey: More Than Two-Thirds of Senior Living Facilities Say They Can’t Access Personal Protective Equipment Needed for COVID-19 Containment Plans
Premier Inc. Survey: More Than Two-Thirds of Senior Living Facilities Say They Can’t Access Personal Protective Equipment Needed for COVID-19 Containment Plans


Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that more than two-thirds of senior living facilities in the United States cannot obtain

Agilent Introduces CrossLab Connect Services for Lab-wide Asset Monitoring
Agilent Introduces CrossLab Connect Services for Lab-wide Asset Monitoring


Agilent Technologies Inc. (NYSE: A) announced today an extension to its digital lab capabilities with Agilent CrossLab Asset Monitoring, an advanced service for laboratories seeking increased

Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications

Lysogene Announces the Date of Its 2020 General Shareholders’ Meeting and Amends Its Financial Calendar
Lysogene Announces the Date of Its 2020 General Shareholders’ Meeting and Amends Its Financial Calendar


Regulatory News:



Lysogene (FR0013233475 – LYS) (Paris:LYS) today announced the amendment of its corporate agenda* for 2020. The annual results for 2019 will be issued on 22 April 2020 instead of